Daxor Stock Today
| DXR Stock | USD 7.91 0.22 2.71% |
Performance0 of 100
| Odds Of DistressLess than 4
|
Daxor is selling at 7.91 as of the 30th of January 2025; that is 2.71% down since the beginning of the trading day. The stock's lowest day price was 7.91. Daxor has only four percent chance of going through some form of financial distress over the next 2 years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 17th of March 1992 | Category Healthcare | Classification Health Care |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corp is traded on NASDAQ Exchange in the United States. The company has 4.84 M outstanding shares of which 13.15 K shares are currently shorted by investors with about 1.87 days to cover. More on Daxor
Moving together with Daxor Stock
Moving against Daxor Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Daxor Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Michael Feldschuh | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDaxor can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Daxor's financial leverage. It provides some insight into what part of Daxor's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Daxor (DXR) is traded on NASDAQ Exchange in USA. It is located in 109 Meco Lane, Oak Ridge, TN, United States, 37830 and employs 16 people. Daxor is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 38.28 M. Daxor runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 4.84 M outstanding shares of which 13.15 K shares are currently shorted by investors with about 1.87 days to cover.
Daxor has about 59.62 K in cash with (3.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Daxor Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Daxor is $38.28 Million. Daxor retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check Daxor Ownership Details
Daxor Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vanguard Group Inc | 2024-09-30 | 48.8 K | |
| Renaissance Technologies Corp | 2024-09-30 | 14.8 K | |
| Keyes Stange & Wooten Wealth Management Llc | 2024-09-30 | 14.6 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 7.2 K | |
| Ubs Group Ag | 2024-09-30 | 1.2 K | |
| Princeton Global Asset Management Llc | 2024-09-30 | 500 | |
| Jones Financial Companies Lllp | 2024-09-30 | 100.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 5.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.0 | |
| Wells Fargo & Co | 2024-09-30 | 0.0 |
Daxor Historical Income Statement
Daxor Stock Against Markets
Daxor Corporate Directors
| James Lombard | Independent Director | Profile | |
| Bernhard Saxe | Independent Director | Profile | |
| Robert Willens | Independent Director | Profile | |
| Jonathan Feldschuh | Chief Scientific Officer, Director | Profile |
Additional Tools for Daxor Stock Analysis
When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.